David Stuart

David has more than eight years of corporate finance and capital markets experience supporting debt and equity transactions for various industries including technology, telecommunications, life sciences, renewable energy and consumer products. His experience includes negotiating and facilitating transaction closings for private equity, venture capital and financial institutions across North America.

In May 2020, David was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.

5 things to know in life sciences: Week of March 15

Mar. 19, 2021 by Steve Kemler, Adam Lohr and David Stuart

This week we highlight possible heightened scrutiny related to pharma mergers, top drugs losing their exclusivity this year, artificial intelligence-powered hearing aids and more. … READ MORE >

5 things to know in life sciences: Week of March 8

Mar. 11, 2021 by Steve Kemler, Adam Lohr and David Stuart

This week we examine COVID-19 variants, heightened scrutiny on accelerated approval phase 4 confirmatory trials, gaps in the understanding of racial and ethnic representation in vaccine trials, tiny cancer-fighting robots and more. … READ MORE >

5 things to know in life sciences: Week of March 1

Mar. 4, 2021 by Steve Kemler, Adam Lohr and David Stuart

In this week’s roundup we look at new data coming out of the U.K. and Israel on their COVID-19 vaccination programs’ results. We also highlight improvements in public perception of the pharmaceutical industry, a new executive order on supply chains and more. … READ MORE >

5 things to know in life sciences: Week of Feb. 22

Feb. 26, 2021 by Steve Kemler, Adam Lohr and David Stuart

In this week’s roundup we look at the latest news on Johnson & Johnson’s vaccine, a federal effort to expand genomic sequencing to track new COVID-19 variants, a major merger in the industry, and more.
… READ MORE >

5 things to know in life sciences: Week of Feb. 15

Feb. 19, 2021 by Steve Kemler, Adam Lohr and David Stuart

In this week’s roundup we look at promising results in a clinical trial leveraging an existing diabetes drug to treat obesity, a new and less invasive treatment for sleep apnea, the impact of the pandemic on oncology trials and more. … READ MORE >

5 things to know in life sciences: Week of Feb. 8

Feb. 11, 2021 by Steve Kemler, Adam Lohr and David Stuart

Recent industry news includes the impact of new COVID-19 variants on existing vaccines for the disease, the outlook for drug pricing reforms under the Biden administration, and the promise of 3D-printed hearts. … READ MORE >

Tech jobs have not been spared in the pandemic, but growth of remote work helps some

May. 29, 2020 by Kurt Shenk, Davis Nordell, Victor Kao and David Stuart

Before COVID-19, unemployment in the technology sector was at a five-decade low and was far lower than the overall U.S. unemployment rate. Though unemployment has risen for some parts of the technology sector as the pandemic has gripped the country, companies are still hiring for other roles. Job postings for … … READ MORE >

« Previous Page

Search

David Stuart

5 things to know in life sciences: Week of March 15

5 things to know in life sciences: Week of March 8

5 things to know in life sciences: Week of March 1

5 things to know in life sciences: Week of Feb. 22

5 things to know in life sciences: Week of Feb. 15

5 things to know in life sciences: Week of Feb. 8

Tech jobs have not been spared in the pandemic, but growth of remote work helps some

About The Real Economy Blog

David Stuart

Footer

About The Real Economy Blog